PRDM proteins: Important players in differentiation and disease

BioEssays

Volumn 34, Issue 1, 2012, Pages 50-60

  Fog, Cathrine K ^a   Galli, Giorgio G ^a   Lund, Anders H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Differentiation; Epigenetics; PRDM; Transcription

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; ISOPROTEIN; NUCLEIC ACID BINDING PROTEIN; POSITIVE REGULATORY DOMAIN CONTAINING GENE WITH ZINC FINGER; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CRYSTAL STRUCTURE; EMBRYONIC STEM CELL; GENETIC REGULATION; HEMATOPOIESIS; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOID CELL; MEDULLOBLASTOMA; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIMORDIAL GERM CELL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SMOOTH MUSCLE FIBER; STOMACH CANCER; TISSUE DIFFERENTIATION; TRANSCRIPTION REGULATION;

ADIPOSE TISSUE, BROWN; ANIMALS; BLOOD VESSELS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HISTONES; HUMANS; ISOENZYMES; METHYLATION; MICE; MICE, TRANSGENIC; NEOPLASMS; ORGAN SPECIFICITY; PROTEIN METHYLTRANSFERASES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 83455259343     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201100107     Document Type: Review

References (122)

1. Huang S. 2002. Histone methyltransferases, diet nutrients and tumour suppressors. Nat Rev Cancer 2: 469- 76.
2. Wu H, Min J, Lunin VV, Antoshenko T, et al. 2010. Structural biology of human H3K9 methyltransferases. PLoS One 5: e8570.
3. Kinameri E, Inoue T, Aruga J, Imayoshi I, et al. 2008. Prdm proto-oncogene transcription factor family expression and interaction with the Notch-Hes pathway in mouse neurogenesis. PLoS One 3: e3859.
4. Fumasoni I, Meani N, Rambaldi D, Scafetta G, et al. 2007. Family expansion and gene rearrangements contributed to the functional specialization of PRDM genes in vertebrates. BMC Evol Biol 7: 187.
5. Briknarova K, Atwater DZ, Glicken JM, Maynard SJ, et al. 2011. The PR/SET domain in PRDM4 is preceded by a zinc knuckle. Proteins 79: 2341- 5.
6. Kim KC, Geng L, Huang S. 2003. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 63: 7619- 23.
7. Eom GH, Kim K, Kim SM, Kee HJ, et al. 2009. Histone methyltransferase PRDM8 regulates mouse testis steroidogenesis. Biochem Biophys Res Commun 388: 131- 6.
8. Hayashi K, Yoshida K, Matsui Y. 2005. A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. Nature 438: 374- 8.
9. Gyory I, Wu J, Fejer G, Seto E, et al. 2004. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 5: 299- 308.
10. Duan Z, Person RE, Lee HH, Huang S, et al. 2007. Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol 27: 6889- 902.
11. Davis CA, Haberland M, Arnold MA, Sutherland LB, et al. 2006. PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. Mol Cell Biol 26: 2626- 36.
12. Zhang Y, Stehling-Sun S, Lezon-Geyda K, Juneja SC, et al. 2011. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood 118: 3853- 61.
13. Yu J, Angelin-Duclos C, Greenwood J, Liao J, et al. 2000. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol 20: 2592- 603.
14. Ancelin K, Lange UC, Hajkova P, Schneider R, et al. 2006. Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol 8: 623- 30.
15. Su ST, Ying HY, Chiu YK, Lin FR, et al. 2009. Involvement of histone demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell differentiation. Mol Cell Biol 29: 1421- 31.
16. Wu Y, Ferguson JE, 3rd, Wang H, Kelley R, et al. 2008. PRDM6 is enriched in vascular precursors during development and inhibits endothelial cell proliferation, survival, and differentiation. J Mol Cell Cardiol 44: 47- 58.
17. Brayer KJ, Segal DJ. 2008. Keep your fingers off my DNA: protein-protein interactions mediated by C2H2 zinc finger domains. Cell Biochem Biophys 50: 111- 31.
18. Ren B, Chee KJ, Kim TH, Maniatis T. 1999. PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev 13: 125- 37.
19. Kajimura S, Seale P, Kubota K, Lunsford E, et al. 2009. Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. Nature 460: 1154- 8.
20. Seale P, Bjork B, Yang W, Kajimura S, et al. 2008. PRDM16 controls a brown fat/skeletal muscle switch. Nature 454: 961- 7.
21. Chia NY, Chan YS, Feng B, Lu X, et al. 2010. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature 468: 316- 20.
22. Ma Z, Swigut T, Valouev A, Rada-Iglesias A, et al. 2010. Sequence-specific regulator Prdm14 safeguards mouse ESCs from entering extraembryonic endoderm fates. Nat Struct Mol Biol 18: 120- 7.
23. Tsuneyoshi N, Sumi T, Onda H, Nojima H, et al. 2008. PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells. Biochem Biophys Res Commun 367: 899- 905.
24. Hayashi K, de Sousa Lopes SM, Surani MA. 2007. Germ cell specification in mice. Science 316: 394- 6.
25. Ohinata Y, Payer B, O'Carroll D, Ancelin K, et al. 2005. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature 436: 207- 13.
26. Yamaji M, Seki Y, Kurimoto K, Yabuta Y, et al. 2008. Critical function of Prdm14 for the establishment of the germ cell lineage in mice. Nat Genet 40: 1016- 22.
27. Baudat F, Buard J, Grey C, Fledel-Alon A, et al. 2010. PRDM9 is a major determinant of meiotic recombination hotspots in humans and mice. Science 327: 836- 40.
28. Myers S, Bowden R, Tumian A, Bontrop RE, et al. 2010. Drive against hotspot motifs in primates implicates the PRDM9 gene in meiotic recombination. Science 327: 876- 9.
29. Berg IL, Neumann R, Lam KW, Sarbajna S, et al. 2010. PRDM9 variation strongly influences recombination hot-spot activity and meiotic instability in humans. Nat Genet 42: 859- 63.
30. Kajimura S, Seale P, Spiegelman BM. 2010. Transcriptional control of brown fat development. Cell Metab 11: 257- 62.
31. Kajimura S, Seale P, Tomaru T, Erdjument-Bromage H, et al. 2008. Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev 22: 1397- 409.
32. Seale P, Kajimura S, Yang W, Chin S, et al. 2007. Transcriptional control of brown fat determination by PRDM16. Cell Metab 6: 38- 54.
33. Seale P, Conroe HM, Estall J, Kajimura S, et al. 2011. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 121: 96- 105.
34. Sun XJ, Xu PF, Zhou T, Hu M, et al. 2008. Genome-wide survey and developmental expression mapping of zebrafish SET domain-containing genes. PLoS One 3: e1499.
35. Hernandez-Lagunas L, Choi IF, Kaji T, Simpson P, et al. 2005. Zebrafish narrow minded disrupts the transcription factor prdm1 and is required for neural crest and sensory neuron specification. Dev Biol 278: 347- 57.
36. Komai T, Iwanari H, Mochizuki Y, Hamakubo T, et al. 2009. Expression of the mouse PR domain protein Prdm8 in the developing central nervous system. Gene Expr Patterns 9: 503- 14.
37. Park JA, Kim KC. Expression patterns of PRDM10 during mouse embryonic development. BMB Rep 43: 29- 33.
38. Behrends U, Schneider I, Rossler S, Frauenknecht H, et al. 2003. Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Int J Cancer 106: 244- 51.
39. Chuikov S, Levi BP, Smith ML, Morrison SJ. 2010. Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. Nat Cell Biol 12: 999- 1006.
40. Yang XH, Huang S. 1999. PFM1 (PRDM4), a new member of the PR-domain family, maps to a tumor suppressor locus on human chromosome 12q23-q24.1. Genomics 61: 319- 25.
41. Chittka A, Arevalo JC, Rodriguez-Guzman M, Perez P, et al. 2004. The p75NTR-interacting protein SC1 inhibits cell cycle progression by transcriptional repression of cyclin E. J Cell Biol 164: 985- 96.
42. Orkin SH, Zon LI. 2008. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132: 631- 44.
43. Fears S, Mathieu C, Zeleznik-Le N, Huang S, et al. 1996. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 93: 1642- 7.
44. Goyama S, Yamamoto G, Shimabe M, Sato T, et al. 2008. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3: 207- 20.
45. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, et al. 1997. The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 65: 55- 70.
46. Yuasa H, Oike Y, Iwama A, Nishikata I, et al. 2005. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24: 1976- 87.
47. Laricchia-Robbio L, Nucifora G. 2008. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis 40: 141- 7.
48. Buonamici S, Li D, Chi Y, Zhao R, et al. 2004. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 114: 713- 9.
49. Laricchia-Robbio L, Fazzina R, Li D, Rinaldi CR, et al. 2006. Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. Mol Cell Biol 26: 7658- 66.
50. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. 2009. EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 69: 1633- 42.
51. Cuenco GM, Ren R. 2004. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene 23: 569- 79.
52. Aguilo F, Avagyan S, Labar A, Sevilla A, et al. 2011. Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood 117: 5057- 66.
53. Deneault E, Cellot S, Faubert A, Laverdure JP, et al. 2009. A functional screen to identify novel effectors of hematopoietic stem cell activity. Cell 137: 369- 79.
54. Turner CA, Jr., Mack DH, Davis MM. 1994. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77: 297- 306.
55. Chang DH, Angelin-Duclos C, Calame K. 2000. BLIMP-1: trigger for differentiation of myeloid lineage. Nat Immunol 1: 169- 76.
56. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, et al. 2003. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19: 607- 20.
57. Martins GA, Cimmino L, Shapiro-Shelef M, Szabolcs M, et al. 2006. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat Immunol 7: 457- 65.
58. Rutishauser RL, Martins GA, Kalachikov S, Chandele A, et al. 2009. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 31: 296- 308.
59. Kallies A, Carotta S, Huntington ND, Bernard NJ, et al. 2011. A role for Blimp1 in the transcriptional network controlling natural killer cell maturation. Blood 117: 1869- 79.
60. Shapiro-Shelef M, Calame K. 2005. Regulation of plasma-cell development. Nat Rev Immunol 5: 230- 42.
61. Crotty S, Johnston RJ, Schoenberger SP. 2010. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 11: 114- 20.
62. Leung KN, Mak NK, Fung MC. 2005. Cytokines in the differentiation therapy of leukemia: from laboratory investigations to clinical applications. Crit Rev Clin Lab Sci 42: 473- 514.
63. Lenz G, Staudt LM. 2010. Aggressive lymphomas. N Engl J Med 362: 1417- 29.
64. Mandelbaum J, Bhagat G, Tang H, Mo T, et al. 2010. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18: 568- 79.
65. Calado DP, Zhang B, Srinivasan L, Sasaki Y, et al. 2010. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18: 580- 9.
66. Pasqualucci L, Compagno M, Houldsworth J, Monti S, et al. 2006. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203: 311- 7.
67. Tam W, Gomez M, Chadburn A, Lee JW, et al. 2006. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107: 4090- 100.
68. Nie K, Zhang T, Allawi H, Gomez M, et al. 2010. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol 177: 1470- 9.
69. Garcia JF, Roncador G, Sanz AI, Maestre L, et al. 2006. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 91: 467- 74.
70. D'Costa K, Emslie D, Metcalf D, Smyth GK, et al. 2009. Blimp1 is limiting for transformation in a mouse plasmacytoma model. Blood 113: 5911- 9.
71. Gyory I, Fejer G, Ghosh N, Seto E, et al. 2003. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol 170: 3125- 33.
72. Zhang YW, Xie HQ, Chen Y, Jiao B, et al. 2010. Loss of promoter methylation contributes to the expression of functionally impaired PRDM1beta isoform in diffuse large B-cell lymphoma. Int J Hematol 92: 439- 44.
73. Wieser R. 2007. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396: 346- 57.
74. Arai S, Yoshimi A, Shimabe M, Ichikawa M, et al. 2011. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117: 6304- 14.
75. Jin G, Yamazaki Y, Takuwa M, Takahara T, et al. 2007. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109: 3998- 4005.
76. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, et al. 2011. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117: 3617- 28.
77. Louz D, van den Broek M, Verbakel S, Vankan Y, et al. 2000. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia 14: 1876- 84.
78. Du Y, Jenkins NA, Copeland NG. 2005. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106: 3932- 9.
79. Shing DC, Trubia M, Marchesi F, Radaelli E, et al. 2007. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest 117: 3696- 707.
80. Nishikata I, Sasaki H, Iga M, Tateno Y, et al. 2003. A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood 102: 3323- 32.
81. Nishikata I, Nakahata S, Saito Y, Kaneda K, et al. 2011. Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation. Oncogene 30: 4194- 207.
82. Yoshida M, Nosaka K, Yasunaga J, Nishikata I, et al. 2004. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood 103: 2753- 60.
83. Steele-Perkins G, Fang W, Yang XH, Van Gele M, et al. 2001. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 15: 2250- 62.
84. Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, et al. 2009. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression. J Hematol Oncol 2: 28.
85. Pastural E, Takahashi N, Dong WF, Bainbridge M, et al. 2007. RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. Oncogene 26: 1586- 94.
86. Chadwick RB, Jiang GL, Bennington GA, Yuan B, et al. 2000. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci USA 97: 2662- 7.
87. Jiang GL, Huang S. 2001. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers. Cancer Res 61: 1796- 8.
88. Carling T, Kim KC, Yang XH, Gu J, et al. 2004. A histone methyltransferase is required for maximal response to female sex hormones. Mol Cell Biol 24: 7032- 42.
89. Deng Q, Huang S. 2004. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 23: 4903- 10.
90. Watanabe Y, Toyota M, Kondo Y, Suzuki H, et al. 2007. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 13: 4786- 94.
91. Cheng HY, Chen XW, Cheng L, Liu YD, et al. 2010. DNA methylation and carcinogenesis of PRDM5 in cervical cancer. J Cancer Res Clin Oncol 136: 1821- 5.
92. Watanabe Y, Kim HS, Castoro RJ, Chung W, et al. 2009. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 136: 2149- 58.
93. Meani N, Pezzimenti F, Deflorian G, Mione M, et al. 2009. The tumor suppressor PRDM5 regulates Wnt signaling at early stages of zebrafish development. PLoS One 4: 273.
94. Burkitt Wright EM, Spencer HL, Daly SB, Manson FD, et al. 2011. Mutations in PRDM5 in brittle cornea syndrome identify a pathway regulating extracellular matrix development and maintenance. Am J Hum Genet 88: 767- 77.
95. Clevers H. 2006. Wnt/beta-catenin signaling in development and disease. Cell 127: 469- 80.
96. Dettman EJ, Justice MJ. 2008. The zinc finger SET domain gene Prdm14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32. PLoS One 3: e3823.
97. Dettman EJ, Simko SJ, Ayanga B, Carofino BL, et al. 2011. Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors. Oncogene 30: 2859- 73.
98. Nishikawa N, Toyota M, Suzuki H, Honma T, et al. 2007. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 67: 9649- 57.
99. Kuo TC, Calame KL. 2004. B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J Immunol 173: 5556- 63.
100. Gupta S, Anthony A, Pernis AB. 2001. Stage-specific modulation of IFN-regulatory factor 4 function by Kruppel-type zinc finger proteins. J Immunol 166: 6104- 11.
101. Medici N, Abbondanza C, Nigro V, Rossi V, et al. 1999. Identification of a DNA binding protein cooperating with estrogen receptor as RIZ (retinoblastoma interacting zinc finger protein). Biochem Biophys Res Commun 264: 983- 9.
102. Huang S, Shao G, Liu L. 1998. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem 273: 15933- 9.
103. Buyse IM, Shao G, Huang S. 1995. The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc Natl Acad Sci USA 92: 4467- 71.
104. Cattaneo F, Nucifora G. 2008. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 105: 344- 52.
105. Funabiki T, Kreider BL, Ihle JN. 1994. The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Oncogene 9: 1575- 81.
106. Delwel R, Funabiki T, Kreider BL, Morishita K, et al. 1993. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 13: 4291- 300.
107. Chi Y, Senyuk V, Chakraborty S, Nucifora G. 2003. EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity. J Biol Chem 278: 49806- 11.
108. Chakraborty S, Senyuk V, Sitailo S, Chi Y, et al. 2001. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem 276: 44936- 43.
109. Palmer S, Brouillet JP, Kilbey A, Fulton R, et al. 2001. Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins. J Biol Chem 276: 25834- 40.
110. Senyuk V, Premanand K, Xu P, Qian Z, et al. 2011. The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One 6: e20793.
111. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, et al. 2011. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 117: 234- 41.
112. Vinatzer U, Taplick J, Seiser C, Fonatsch C, et al. 2001. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol 114: 566- 73.
113. Kurokawa M, Mitani K, Yamagata T, Takahashi T, et al. 2000. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19: 2958- 68.
114. Spensberger D, Vermeulen M, Le Guezennec X, Beekman R, et al. 2008. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD. Biochemistry 47: 6418- 26.
115. Shimahara A, Yamakawa N, Nishikata I, Morishita K. 2010. Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2. J Biol Chem 285: 16967- 77.
116. Senyuk V, Sinha KK, Li D, Rinaldi CR, et al. 2007. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer Res 67: 5658- 66.
117. Alliston T, Ko TC, Cao Y, Liang YY, et al. 2005. Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1. J Biol Chem 280: 24227- 37.
118. Kurokawa M, Mitani K, Irie K, Matsuyama T, et al. 1998. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 394: 92- 6.
119. McGilvray R, Walker M, Bartholomew C. 2007. UXT interacts with the transcriptional repressor protein EVI1 and suppresses cell transformation. FEBS J 274: 3960- 71.
120. Chittka A, Chao MV. 1999. Identification of a zinc finger protein whose subcellular distribution is regulated by serum and nerve growth factor. Proc Natl Acad Sci USA 96: 10705- 10.
121. Takahata M, Inoue Y, Tsuda H, Imoto I, et al. 2009. SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem 284: 3334- 44.
122. Warner DR, Horn KH, Mudd L, Webb CL, et al. 2007. PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic orofacial tissue. Biochim Biophys Acta 1773: 814- 20.